Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

HK Short Interest: BOC, Wuxi Biologics/Apptec

HK Short Interest: Alibaba, China Overseas Land

HK Short Interest: Wuxi Biologics and Wuxi Apptec

HK Short Interest: GCL-Poly, XPeng, Beigene

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

Hong kong Financials / Quantitative Analysis

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Jan 14. </li>
<li>Top short increases and decreases were tabulated for one week and four week period. </li>
<li>We highlight the short interest increases for HSBC and Wuxi Biologics in the latest short report.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Jan 14. 
Top short increases and decreases were tabulated for one week and four week period. 
We highlight the short interest increases for HSBC and Wuxi Biologics in the latest short report.


HK Short Interest: HSBC, Wuxi Biologics